Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while JPMorgan Ultra Short Income ETF trades at $50.44. Which is the better fit depends on your goals.
| ALNY | JPST | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $50.78 |
52-Week Low | $278.09 | $50.40 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.45 with no recent price change. The technical outlook is bearish based on moving averages, while oscillators are neutral. The fund focuses on high-quality, short-term bonds, offering a cash alternative with low duration risk. Recent news highlights its role in rising rate environments and strong flows into active ETFs.
The outlook for JPST is stable, appealing to risk-averse investors seeking income and capital preservation amid interest rate uncertainty. Key risks include interest rate sensitivity and credit spread changes. Institutional interest is growing, but the bearish technical signal warrants caution for short-term traders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
